Press Release: Sanofi’s Sarclisa Subcutaneous Approved in the EU as the First Anticancer Treatment Administered via an on-Body Injector
16 Articles
16 Articles
This solution is being examined by regulatory authorities in several countries, including the United States, Japan and China, the pharmaceutical group needs.
On Monday, Sanofi announced that it had obtained the approval of the European authorities for Sarclisa, a monoclonal antibody. Its particularity: it is the first anticancer treatment to be given via a portable injector. Launched in 2020, Sarclisa has already been approved in nearly 60 countries and prescribed to 70,000 patients worldwide. - "More flexibility": a first anticancer treatment by portable injector approved by the EU (Health and well-…
This subcutaneous version of the Sarclisa anticancer treatment has so far been administered in hospital. It can now be given by hand injector.
Sanofi has obtained the approval of the European Commission for a new formulation of its anticancer treatment Sarclisa, which can be administered via a portable subcutaneous injector, a step forward that could facilitate the management of patients with multiple myeloma at home or in an outpatient setting.
leprogres.fr
This medicine was developed to treat multiple myeloma, a form of plasma cell cancer, caused by abnormal cell production within the plasma.
Coverage Details
Bias Distribution
- 62% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
